-
- Michael A. Fischbach
- Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
-
- Christopher T. Walsh
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
説明
<jats:title>Toward New Scaffolds</jats:title> <jats:p> Most existing antibiotics are derived from a small number of core molecular structures or scaffolds. As more and more pathogens emerge that are resistant to existing antibiotics, <jats:bold>Fischbach and Walsh</jats:bold> (p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" page="1089" related-article-type="in-this-issue" vol="325" xlink:href="10.1126/science.1176667">1089</jats:related-article> ) review why renewed efforts must be made to find not only new antibiotics but new scaffolds. Approaches in the areas of natural products, synthesis, and target-based discovery are all yielding promising antibiotics candidates. The battle against resistance should also involve researching narrow-spectrum antibiotics and using combination therapies to extend the usefulness of drugs with high intrinsic resistance rates. </jats:p>
収録刊行物
-
- Science
-
Science 325 (5944), 1089-1093, 2009-08-28
American Association for the Advancement of Science (AAAS)
